1939 related articles for article (PubMed ID: 23932184)
21. Genetic studies of quantitative MCI and AD phenotypes in ADNI: Progress, opportunities, and plans.
Saykin AJ; Shen L; Yao X; Kim S; Nho K; Risacher SL; Ramanan VK; Foroud TM; Faber KM; Sarwar N; Munsie LM; Hu X; Soares HD; Potkin SG; Thompson PM; Kauwe JS; Kaddurah-Daouk R; Green RC; Toga AW; Weiner MW;
Alzheimers Dement; 2015 Jul; 11(7):792-814. PubMed ID: 26194313
[TBL] [Abstract][Full Text] [Related]
22. Japanese and North American Alzheimer's Disease Neuroimaging Initiative studies: Harmonization for international trials.
Iwatsubo T; Iwata A; Suzuki K; Ihara R; Arai H; Ishii K; Senda M; Ito K; Ikeuchi T; Kuwano R; Matsuda H; ; Sun CK; Beckett LA; Petersen RC; Weiner MW; Aisen PS; Donohue MC;
Alzheimers Dement; 2018 Aug; 14(8):1077-1087. PubMed ID: 29753531
[TBL] [Abstract][Full Text] [Related]
23. Impact of the Alzheimer's Disease Neuroimaging Initiative, 2004 to 2014.
Weiner MW; Veitch DP; Aisen PS; Beckett LA; Cairns NJ; Cedarbaum J; Donohue MC; Green RC; Harvey D; Jack CR; Jagust W; Morris JC; Petersen RC; Saykin AJ; Shaw L; Thompson PM; Toga AW; Trojanowski JQ;
Alzheimers Dement; 2015 Jul; 11(7):865-84. PubMed ID: 26194320
[TBL] [Abstract][Full Text] [Related]
24. Cerebrospinal fluid synaptosomal-associated protein 25 is a key player in synaptic degeneration in mild cognitive impairment and Alzheimer's disease.
Zhang H; Therriault J; Kang MS; Ng KP; Pascoal TA; Rosa-Neto P; Gauthier S;
Alzheimers Res Ther; 2018 Aug; 10(1):80. PubMed ID: 30115118
[TBL] [Abstract][Full Text] [Related]
25. Combining MRI and CSF measures for classification of Alzheimer's disease and prediction of mild cognitive impairment conversion.
Westman E; Muehlboeck JS; Simmons A
Neuroimage; 2012 Aug; 62(1):229-38. PubMed ID: 22580170
[TBL] [Abstract][Full Text] [Related]
26. Clinical Core of the Alzheimer's Disease Neuroimaging Initiative: progress and plans.
Aisen PS; Petersen RC; Donohue MC; Gamst A; Raman R; Thomas RG; Walter S; Trojanowski JQ; Shaw LM; Beckett LA; Jack CR; Jagust W; Toga AW; Saykin AJ; Morris JC; Green RC; Weiner MW;
Alzheimers Dement; 2010 May; 6(3):239-46. PubMed ID: 20451872
[TBL] [Abstract][Full Text] [Related]
27. Multiple Effect of APOE Genotype on Clinical and Neuroimaging Biomarkers Across Alzheimer's Disease Spectrum.
Liu Y; Tan L; Wang HF; Liu Y; Hao XK; Tan CC; Jiang T; Liu B; Zhang DQ; Yu JT;
Mol Neurobiol; 2016 Sep; 53(7):4539-47. PubMed ID: 26298664
[TBL] [Abstract][Full Text] [Related]
28. The Alzheimer's Disease Neuroimaging Initiative 2 Biomarker Core: A review of progress and plans.
Kang JH; Korecka M; Figurski MJ; Toledo JB; Blennow K; Zetterberg H; Waligorska T; Brylska M; Fields L; Shah N; Soares H; Dean RA; Vanderstichele H; Petersen RC; Aisen PS; Saykin AJ; Weiner MW; Trojanowski JQ; Shaw LM;
Alzheimers Dement; 2015 Jul; 11(7):772-91. PubMed ID: 26194312
[TBL] [Abstract][Full Text] [Related]
29. Identification of prognostic factors to predict cognitive decline of patients with early Alzheimer's disease in the Japanese Alzheimer's Disease Neuroimaging Initiative study.
Yagi T; Kanekiyo M; Ito J; Ihara R; Suzuki K; Iwata A; Iwatsubo T; Aoshima K; ;
Alzheimers Dement (N Y); 2019; 5():364-373. PubMed ID: 31440579
[TBL] [Abstract][Full Text] [Related]
30. Longitudinal Exposure-Response Modeling of Multiple Indicators of Alzheimer's Disease Progression.
Polhamus DG; Dolton MJ; Rogers JA; Honigberg L; Jin JY; Quartino A
J Prev Alzheimers Dis; 2023; 10(2):212-222. PubMed ID: 36946448
[TBL] [Abstract][Full Text] [Related]
31. 18F-Flortaucipir PET Associations with Cerebrospinal Fluid, Cognition, and Neuroimaging in Mild Cognitive Impairment due to Alzheimer's Disease.
Okafor M; Nye JA; Shokouhi M; Shaw LM; Goldstein F; Hajjar I
J Alzheimers Dis; 2020; 74(2):589-601. PubMed ID: 32065800
[TBL] [Abstract][Full Text] [Related]
32. Disease trajectories in elders with suspected non-Alzheimer's pathophysiology and its comparison with Alzheimer's disease pathophysiology: a longitudinal study.
Li JQ; Song JH; Suckling J; Wang YJ; Zuo CT; Zhang C; Gao J; Song YQ; Xie AM; Tan L; Yu JT
Res Sq; 2023 Mar; ():. PubMed ID: 37034751
[TBL] [Abstract][Full Text] [Related]
33. Alzheimer's Disease Normative Cerebrospinal Fluid Biomarkers Validated in PET Amyloid-β Characterized Subjects from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study.
Li QX; Villemagne VL; Doecke JD; Rembach A; Sarros S; Varghese S; McGlade A; Laughton KM; Pertile KK; Fowler CJ; Rumble RL; Trounson BO; Taddei K; Rainey-Smith SR; Laws SM; Robertson JS; Evered LA; Silbert B; Ellis KA; Rowe CC; Macaulay SL; Darby D; Martins RN; Ames D; Masters CL; Collins S;
J Alzheimers Dis; 2015; 48(1):175-87. PubMed ID: 26401938
[TBL] [Abstract][Full Text] [Related]
34. Time course of phosphorylated-tau181 in blood across the Alzheimer's disease spectrum.
Moscoso A; Grothe MJ; Ashton NJ; Karikari TK; Rodriguez JL; Snellman A; Suárez-Calvet M; Zetterberg H; Blennow K; Schöll M;
Brain; 2021 Feb; 144(1):325-339. PubMed ID: 33257949
[TBL] [Abstract][Full Text] [Related]
35. MarkVCID cerebral small vessel consortium: I. Enrollment, clinical, fluid protocols.
Wilcock D; Jicha G; Blacker D; Albert MS; D'Orazio LM; Elahi FM; Fornage M; Hinman JD; Knoefel J; Kramer J; Kryscio RJ; Lamar M; Moghekar A; Prestopnik J; Ringman JM; Rosenberg G; Sagare A; Satizabal CL; Schneider J; Seshadri S; Sur S; Tracy RP; Yasar S; Williams V; Singh H; Mazina L; Helmer KG; Corriveau RA; Schwab K; Kivisäkk P; Greenberg SM;
Alzheimers Dement; 2021 Apr; 17(4):704-715. PubMed ID: 33480172
[TBL] [Abstract][Full Text] [Related]
36. Predicting missing biomarker data in a longitudinal study of Alzheimer disease.
Lo RY; Jagust WJ;
Neurology; 2012 May; 78(18):1376-82. PubMed ID: 22491869
[TBL] [Abstract][Full Text] [Related]
37. What are the Most Frequently Impaired Markers of Neurodegeneration in ADNI Subjects?
Andriuta D; Moullart V; Schraen S; Devendeville A; Meyer ME; Godefroy O;
J Alzheimers Dis; 2016; 51(3):793-800. PubMed ID: 26923012
[TBL] [Abstract][Full Text] [Related]
38. [Preclinical AD and Biomarker; from J-ADNI to AMED Preclinical Study].
Suzuki K
Brain Nerve; 2017 Jul; 69(7):691-700. PubMed ID: 28739982
[TBL] [Abstract][Full Text] [Related]
39. Association Between Longitudinal Plasma Neurofilament Light and Neurodegeneration in Patients With Alzheimer Disease.
Mattsson N; Cullen NC; Andreasson U; Zetterberg H; Blennow K
JAMA Neurol; 2019 Jul; 76(7):791-799. PubMed ID: 31009028
[TBL] [Abstract][Full Text] [Related]
40. Basal forebrain atrophy correlates with amyloid β burden in Alzheimer's disease.
Kerbler GM; Fripp J; Rowe CC; Villemagne VL; Salvado O; Rose S; Coulson EJ;
Neuroimage Clin; 2015; 7():105-13. PubMed ID: 25610772
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
